Piramal Enterprises GSK Pharma Biocon S&P BSE Healthcare While most pharma companies have turned risky on account of regulatory clamps, investors have switched to companies with healthy pipeline and strong track record withFDA.GSKPharmaseemedtobe the preferred choice as a defensive stock. That probably explains why despite most analysts having a bearish view of the company’s prospects, the stock emerged to be the top gainer in the sectoral index year-to-date.
On the other hand, Biocon has been preferred for its promising prospects on account of its biosimilars portfolio, commissioning of new facility in Malaysia, and listing of its subsidi- April 28, 2016 ary Syngene. A good Q4 show pushed the stock to a new high on Tuesday.
Piramal Enterprises, with a motley presence in healthcare, financial services and information management, has been preferred for its high profitability and track record of efficient investments. Last week, the company made investments in two cement companies after an earlier investment in solar business – sparking fresh buying interest in the stock.
Biocon and Piramal, with high possibility of continuing good performance, are likely to retain interest even after the regulatory risks for other pharma companies subside.